ACADIA Pharmaceuticals Inc. (ACAD)

51.40
NASDAQ : Health Technology
Prev Close 50.48
Day Low/High 50.50 / 52.49
52 Wk Low/High 14.01 / 53.70
Avg Volume 2.21M
Exchange NASDAQ
Shares Outstanding 154.03M
Market Cap 7.78B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Positive Developments for These 3 Biotech Stocks

Positive Developments for These 3 Biotech Stocks

We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.

2 Attractive Biotechs With Key Study Outcomes on the Horizon

2 Attractive Biotechs With Key Study Outcomes on the Horizon

Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

Quick takes on fourth-quarter results from these 3 biotech names.

8 Stocks Poised to Change Direction

8 Stocks Poised to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns.

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

Time to Marinate the Ice Cubes

Great being here on Daily Diary today. Nice to see a huge rally for once standing in for Dougie as well. Lots of good conversation as the markets close near their highs for the day. Some big moves in the small biotech names that are near and dear to...

A Rash of Biotech News

The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...

3 Good Bargain Stocks With Insider Buying

3 Good Bargain Stocks With Insider Buying

I continue to keep a 'shopping list' at the ready for the next dip in the market.

Multiple Creep... and More

Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Acadia, Dynavax Make the Biotech Mailbag

Acadia, Dynavax Make the Biotech Mailbag

Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.

The Good, the Bad and the Ugly (Monday Edition)

"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: "The Good, the Bad and the Ugly" There was plenty of sector rotation today (but little overall movement), so let's move to the abbreviated Monarch Notes form of "Takeaw...

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

ACAD looks strong enough for a rally at least to the upper $30s.

3 Housing Plays With Solid Earnings

3 Housing Plays With Solid Earnings

These names are building a sound foundation for growth.

My Takeaways and Observations

"I never knew how easy the game of baseball was until I entered the broadcasting booth." -- Mickey Mantle While the markets were relatively flat there was a lot of subsurface action.   The Alternative to the Bullish View. I might be right I might be...

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Keep Biotech Trigger Fingers Holstered

Keep Biotech Trigger Fingers Holstered

Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

Biowreck!

I am not sure if this has broader consequences, but biotech (especially of a speculative -- kind) is spitting the bit, again today.   I have already mentioned Allergan AGN (which I am buying now). Celgene CELG and Gilead Sciences GILD can't rally ei...

Takeaways and Observations

"She's a witch of trouble in electric blue, In her own mad mind she's in love with you. With you. Now what you gonna do? Strange brew, kill what's inside of you." -- Cream, Strange Brew     Strange brew!    You have probably forgotten October, 1987....

Added to Allergan on Weakness

Allergan , a day ahead of its earnings release, is down by over $4 on no apparent news, save a rotation out of biotech. (iShares Nasdaq Biotechnology is -3% or -$7 and we see individual equity declines in Celgene , Gilead , Acadia Pharmaceuticals , ...